<DOC>
	<DOCNO>NCT00785772</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics ( PK ) follow administration gabapentin Japanese epileptic patient renal impairment confirm clinically relevant difference plasma gabapentin concentration simulate population PK model , use evidence dose adjustment patient renal impairment , observe plasma gabapentin concentration .</brief_summary>
	<brief_title>A Post-Marketing Clinical Pharmacokinetics Study Of Gabapentin In Japanese Epileptic Subjects With Renal Impairment</brief_title>
	<detailed_description>Only one subject able enrol . Given enrollment challenge identify additional appropriate subject , discussion hold Japan Pharmaceuticals Medical Devices Agency ( PMDA ) agree PMDA terminate study . The study terminate December 14 , 2010 . The study terminate due safety finding .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Japanese epilepsy patient renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Gabapentin Pharmacokinetics</keyword>
</DOC>